Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
• A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of therapeutic class, route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Chronic Kidney Disease (Chronic Renal Failure) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

List of Tables
List of Figures
Introduction
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Universities/Institutes Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Late Stage Drug Profiles – Companies
Late Stage Drug Profiles – Universities/Institutes
Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer 96

LIST OF TABLES

Number of Products Under Development for Chronic Kidney Disease (Chronic Renal Failure), 2011
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Genzyme Corporation, 2011
F. Hoffmann-La Roche Ltd., 2011
Abbott Laboratories, 2011
United Therapeutics Corporation, 2011
Ash Access Technology, Inc., 2011
Amgen Inc., 2011
Eli Lilly and Company, 2011
Quark Pharmaceuticals, Inc., 2011
AKELA Pharma Inc., 2011
Novartis AG, 2011
Astellas Pharma Inc., 2011
Pfizer Inc., 2011
Cyclacel Pharmaceuticals Inc., 2011
Celldex Therapeutics, Inc., 2011
Dynavax Technologies Corporation, 2011
ProMetic Life Sciences Inc., 2011
LG Life Sciences, Ltd, 2011
Affymax, Inc., 2011
Spectrum Pharmaceuticals, Inc., 2011
AplaGen GmbH, 2011
Ocera Therapeutics, Inc., 2011
Proteon Therapeutics, Inc., 2011
Reata Pharmaceuticals, Inc., 2011
Thrasos, Inc., 2011
Concert Pharmaceuticals, Inc., 2011
CorMedix, Inc., 2011
Vitae Pharmaceuticals, Inc., 2011
Relypsa, Inc., 2011
Stelic Institute & Co., 2011
Vifor Pharma Ltd., 2011
Sorbent Therapeutics, Inc., 2011
InVasc Therapeutics, Inc., 2011
Varinel, Inc., 2011
Iperboreal Pharma srl, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products 91

LIST OF FIGURES

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), 2011
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011 49 Skip to top